Baker Bros. Advisors Reduces $2M in Heron Therapeutics, Inc. ($HRTX)
Key Points
- Baker Bros. Advisors changed its Heron Therapeutics, Inc. ($HRTX) stake by 100.0% last quarter, cutting to 0 shares.
- Wall Street's consensus rating on $HRTX is Buy and an average price target of $3.00.
- $HRTX last traded around $0.40.
Baker Bros. Advisors reduced its position in Heron Therapeutics, Inc. ($HRTX), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Heron Therapeutics, Inc. after selling 4,251,951 shares during the quarter.
Heron Therapeutics, Inc. ($HRTX) Stock
Heron Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.